Mehran beiraghi Beiraghi Toosi

Dr. Mehran beiraghi Beiraghi Toosi

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 April 2017 in Neuropediatrics
Verified
Journal Article
Closed access
PDF file
GRGillian I. Rice
Gillian I. Rice
NKNaoki Kitabayashi
Naoki Kitabayashi
MBMagalie Barth
Magalie Barth
TBTracy A. Briggs
Tracy A. Briggs
ABAnnabel C.E. Burton
Annabel C.E. Burton
YCYanick J. Crow
Yanick J. Crow
We investigated the genetic, phenotypic, and interferon status of 46 patients from 37 families with neurological disease due to mutations in ADAR1. The clinicoradiological phenotype encompassed a spectrum of Aicardi–Goutières syndrome, isolated bilateral striatal necrosis, spastic paraparesis with normal neuroimaging, a progressive spastic dystonic motor disorder, and adult-onset psychological difficulties with intracranial calcification. Homozygous missense mutations were recorded in five families. We observed a p.Pro193Ala variant in the heterozygous state in 22 of 23 families with compound heterozygous mutations. We also ascertained 11 cases from nine families with a p.Gly1007Arg dominant-negative mutation, which occurred de novo in four patients, and was inherited in three families in association with marked phenotypic variability. In 50 of 52 samples from 34 patients, we identified a marked upregulation of type I interferon-stimulated gene transcripts in peripheral blood, with a median interferon score of 16.99 (interquartile range [IQR]: 10.64–25.71) compared with controls (median: 0.93, IQR: 0.57–1.30). Thus, mutations in ADAR1 are associated with a variety of clinically distinct neurological phenotypes presenting from early infancy to adulthood, inherited either as an autosomal recessive or dominant trait. Testing for an interferon signature in blood represents a useful biomarker in this context.

1 January 2011 in Epilepsy Research
Verified
Journal Article
Closed access
JAJavad Akhondian
Javad Akhondian
HKHamidreza Kianifar
Hamidreza Kianifar
MRMohammad Raoofziaee
Mohammad Raoofziaee
AMAmir Moayedpour
Amir Moayedpour
MTMehran beiraghi Beiraghi Toosi
Mehran beiraghi Beiraghi Toosi
MKMohammad Khajedaluee
Mohammad Khajedaluee

1 September 2018 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
SGShereen G Ghosh
Shereen G Ghosh
KBKerstin Becker
Kerstin Becker
HHHe Huang
He Huang
TDTracy Dixon-Salazar
Tracy Dixon-Salazar
GCGuoliang Chai
Guoliang Chai
JGJoseph G Gleeson
Joseph G Gleeson

26 February 2020 in Genetics in Medicine
Verified
Journal Article
Closed access
PDF file
MWMatias Wagner
Matias Wagner
JLJonathan Lévy
Jonathan Lévy
SJSabine Jung-Klawitter
Sabine Jung-Klawitter
SBSomayeh Bakhtiari
Somayeh Bakhtiari
FMFabiola Monteiro
Fabiola Monteiro
TOThomas Opladen
Thomas Opladen

22 June 2020 in European Journal of Human Genetics
Verified
Journal Article
Open access
PDF file
MSMarcello Scala
Marcello Scala
GCGeok Lin Chua
Geok Lin Chua
CCCheen Fei Chin
Cheen Fei Chin
HAHessa S. Alsaif
Hessa S. Alsaif
ABArtem Borovikov
Artem Borovikov
DSDavid L. Silver
David L. Silver
Major Facilitator Superfamily Domain containing 2a (MFSD2A) is an essential endothelial lipid transporter at the blood-brain barrier. Biallelic variants affecting function in MFSD2A cause autosomal recessive primary microcephaly 15 (MCPH15, OMIM# 616486). We sought to expand our knowledge of the phenotypic spectrum of MCPH15 and demonstrate the underlying mechanism of inactivation of the MFSD2A transporter. We carried out detailed analysis of the clinical and neuroradiological features of a series of 27 MCPH15 cases, including eight new individuals from seven unrelated families. Genetic investigation was performed through exome sequencing (ES). Structural insights on the human Mfsd2a model and in-vitro biochemical assays were used to investigate the functional impact of the identified variants. All patients had primary microcephaly and severe developmental delay. Brain MRI showed variable degrees of white matter reduction, ventricular enlargement, callosal hypodysgenesis, and pontine and vermian hypoplasia. ES led to the identification of six novel biallelic MFSD2A variants (NG_053084.1, NM_032793.5: c.556+1G>A, c.748G>T; p.(Val250Phe), c.750_753del; p.(Cys251SerfsTer3), c.977G>A; p.(Arg326His), c.1386_1435del; p.(Gln462HisfsTer17), and c.1478C>T; p.(Pro493Leu)) and two recurrent variants (NM_032793.5: c.593C>T; p.(Thr198Met) and c.476C>T; p.(Thr159Met)). All these variants and the previously reported NM_032793.5: c.490C>A; p.(Pro164Thr) resulted in either reduced MFSD2A expression and/or transport activity. Our study further delineates the phenotypic spectrum of MCPH15, refining its clinical and neuroradiological characterization and supporting that MFSD2A deficiency causes early prenatal brain developmental disruption. We also show that poor MFSD2A expression despite normal transporter activity is a relevant pathomechanism in MCPH15.

28 May 2020 in Genetics in Medicine
Verified
Journal Article
Open access
PDF file
FCFrancisco del Caño-Ochoa
Francisco del Caño-Ochoa
BNBobby G. Ng
Bobby G. Ng
MAMalak Abedalthagafi
Malak Abedalthagafi
MAMohammed Almannai
Mohammed Almannai
RCRonald D. Cohn
Ronald D. Cohn
SRSantiago Ramon-Maiques
Santiago Ramon-Maiques
Purpose Pathogenic autosomal recessive variants in CAD, encoding the multienzymatic protein initiating pyrimidine de novo biosynthesis, cause a severe inborn metabolic disorder treatable with a dietary supplement of uridine. This condition is difficult to diagnose given the large size of CAD with over 1000 missense variants and the nonspecific clinical presentation. We aimed to develop a reliable and discerning assay to assess the pathogenicity of CAD variants and to select affected individuals that might benefit from uridine therapy. Methods Using CRISPR/Cas9, we generated a human CAD-knockout cell line that requires uridine supplements for survival. Transient transfection of the knockout cells with recombinant CAD restores growth in absence of uridine. This system determines missense variants that inactivate CAD and do not rescue the growth phenotype. Results We identified 25 individuals with biallelic variants in CAD and a phenotype consistent with a CAD deficit. We used the CAD-knockout complementation assay to test a total of 34 variants, identifying 16 as deleterious for CAD activity. Combination of these pathogenic variants confirmed 11 subjects with a CAD deficit, for whom we describe the clinical phenotype. Conclusions We designed a cell-based assay to test the pathogenicity of CAD variants, identifying 11 CAD-deficient individuals who could benefit from uridine therapy.